Scinai Immunotherapeutics(SCNI)

Focus: Scinai Immunotherapeutics is an Israel-based public biotech focused on universal influenza vaccines and immunological adjuvants for infectious diseases and vaccines. The company is in early-stage development with minimal clinical pipeline visibility.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Scinai Immunotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Scinai Immunotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Recent News · Scinai Immunotherapeutics(7)

NewsNews

May 20, 2026

Scinai Immunotherapeutics Appoints Eilon Elmalem as Head of Yavne CDMO Facility - citybuzz -

Scinai Immunotherapeutics Appoints Eilon Elmalem as Head of Yavne CDMO Facility  citybuzz -

Help build intelligence for Scinai Immunotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to emerging vaccine technology (universal influenza vaccine) in a high-unmet-need area with pandemic relevance.
Public company status provides equity upside potential and access to capital markets for career trajectory.
Recent strategic expansion into CDMO platform (Yavne facility appointment, May 2026) signals infrastructure build-out and diversification beyond R&D.

Watch Out For

Zero active clinical trials reported (0 Phase 1/2/3 programs) indicates minimal near-term regulatory catalysts or commercialization momentum.
Negative net income of $8.2M (FY 2022) against only $3M R&D spend and $17M cash suggests cash burn concerns and potential runway constraints without new financing.
No open job postings (activeJobCount: 0) signals either hiring freeze, small/contracting headcount, or limited organizational growth.

Generated by Claude from Scinai Immunotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.